+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Preclinical Contract Research Organizations - Global Strategic Business Report

  • PDF Icon

    Report

  • 89 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303873
The global market for Preclinical Contract Research Organizations was estimated at US$7.1 Billion in 2023 and is projected to reach US$11.3 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Preclinical Contract Research Organizations Market - Key Trends & Drivers Summarized

How Are Preclinical Contract Research Organizations (CROs) Shaping The Drug Development Process?

Preclinical Contract Research Organizations (CROs) play a critical role in the drug development pipeline, providing pharmaceutical and biotechnology companies with essential services to support early-stage research. These organizations specialize in conducting preclinical studies that assess the safety, efficacy, and pharmacokinetics of new drug candidates before they proceed to clinical trials. The services offered by preclinical CROs include in vitro and in vivo studies, toxicology testing, pharmacokinetics (PK) and pharmacodynamics (PD) evaluations, bioanalytical services, and regulatory consulting. By outsourcing these complex and resource-intensive activities to specialized CROs, drug developers can streamline their research processes, reduce costs, and focus on core competencies like drug discovery and strategic planning.

The importance of preclinical CROs has grown in tandem with the increasing complexity of drug development. Today's biopharmaceutical landscape is characterized by the development of more specialized and advanced therapies, such as biologics, gene therapies, and personalized medicine. These therapies require highly specialized preclinical testing protocols to evaluate their safety and therapeutic potential.

CROs offer the infrastructure, expertise, and regulatory knowledge necessary to conduct these tests in accordance with Good Laboratory Practice (GLP) standards. As the drug development process becomes more global and regulatory requirements become more stringent, preclinical CROs serve as invaluable partners to companies seeking to navigate these challenges and bring new therapies to market efficiently.

What Technological Innovations Are Driving The Growth Of Preclinical CROs?

Technological advancements are playing a pivotal role in enhancing the capabilities and efficiency of preclinical Contract Research Organizations. One of the most significant innovations impacting this sector is the increased adoption of advanced in silico modeling and simulation techniques. These computational tools allow CROs to predict the biological behavior of drug candidates before initiating costly and time-consuming in vivo studies. By modeling pharmacokinetics, toxicity, and efficacy, these technologies help reduce the number of compounds that progress to animal testing, thereby saving both time and resources. Artificial intelligence (AI) and machine learning are also being integrated into preclinical research to analyze vast datasets, identify potential drug candidates, and optimize study designs.

Another major technological advancement is the growing use of high-throughput screening (HTS) and automated systems in preclinical testing. Automated platforms allow CROs to rapidly screen thousands of compounds for their biological activity, providing quicker results and reducing human error. This automation is particularly valuable for large-scale pharmacokinetics and toxicology studies, where speed and accuracy are critical. Additionally, advancements in imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are enabling more detailed and real-time monitoring of drug effects in animal models, enhancing the accuracy of preclinical studies.

The emergence of 3D cell culture and organ-on-a-chip technologies is also transforming the preclinical landscape. These technologies provide more physiologically relevant models that better mimic human biology compared to traditional 2D cell cultures. By using 3D cell cultures and microfluidic devices that simulate the behavior of human tissues and organs, CROs can conduct more accurate and predictive studies on drug efficacy and toxicity. This not only improves the reliability of preclinical results but also supports the development of more complex therapies like biologics and personalized medicines.

How Are Market Dynamics And Outsourcing Trends Shaping The Role Of Preclinical CROs?

The growing trend of outsourcing preclinical research to CROs is reshaping the global pharmaceutical and biotechnology industries. As drug development costs continue to rise and timelines become more stringent, companies are increasingly looking to preclinical CROs to provide specialized expertise and cost-effective solutions. Outsourcing allows pharmaceutical companies to mitigate the high financial risk associated with preclinical studies, as CROs provide the necessary infrastructure, technology, and regulatory expertise to execute these studies efficiently. This shift toward outsourcing has led to a growing reliance on CROs for comprehensive drug development services, from discovery through to early clinical trials.

One of the key factors driving this trend is the increasing specialization of drug development, particularly with the rise of personalized medicine, gene therapies, and cell-based treatments. These therapies require preclinical testing protocols that go beyond traditional small-molecule drugs, necessitating the use of CROs with specialized capabilities in areas like immunology, genetic engineering, and bioinformatics.

Additionally, as global pharmaceutical companies expand their operations across different regions, they often turn to CROs with a strong presence in specific markets to help navigate regional regulatory requirements and conduct studies in diverse patient populations. The ability of preclinical CROs to manage these complexities allows drug developers to focus on their core research and development efforts while maintaining compliance with regulatory standards.

Moreover, the consolidation of the pharmaceutical industry, with increasing mergers and acquisitions, has also contributed to the rise of preclinical CROs. Smaller biotechnology companies, which may lack the financial and operational resources to conduct in-house preclinical studies, often partner with CROs to advance their drug candidates through the early stages of development. Large pharmaceutical companies also benefit from CRO partnerships by optimizing their resources and focusing on late-stage clinical trials, where the financial stakes are higher. The flexibility and scalability that CROs offer make them attractive partners in a fast-paced, competitive market.

What Factors Are Driving Growth In The Preclinical CRO Market?

The growth in the Preclinical Contract Research Organization (CRO) market is driven by several factors, including technological advancements, rising demand for outsourced services, and the increasing complexity of drug development. One of the primary growth drivers is the growing prevalence of complex and advanced therapies such as biologics, gene therapies, and personalized medicine. These therapies require specialized preclinical testing capabilities, including advanced toxicology, immunogenicity testing, and genetic profiling, which CROs are uniquely positioned to offer. As these therapies become more prevalent, the need for CROs with expertise in these areas continues to grow.

Another key driver of market growth is the rising cost of in-house preclinical testing, which has led pharmaceutical and biotechnology companies to outsource these functions to CROs. Preclinical studies are often resource-intensive, requiring sophisticated laboratory infrastructure, skilled personnel, and strict adherence to regulatory standards. By outsourcing to CROs, companies can reduce capital expenditures, shorten development timelines, and allocate their internal resources to strategic areas of drug discovery and clinical trials. This trend is particularly pronounced among smaller biotech firms and startups, which rely heavily on outsourcing to advance their drug candidates through the preclinical pipeline.

The global expansion of the pharmaceutical industry and the increasing complexity of regulatory requirements are also contributing to the growth of the preclinical CRO market. As pharmaceutical companies seek to enter new markets, they must comply with varying regional regulatory standards. CROs with a strong understanding of local regulations and experience in navigating the complexities of international drug development are in high demand. Additionally, the push for faster drug approvals and the rise of orphan drug designations are driving the need for more efficient preclinical testing, further fueling demand for CRO services.

Lastly, the growing emphasis on reducing animal testing and improving the predictive accuracy of preclinical models is encouraging the adoption of advanced technologies like in silico modeling, organ-on-a-chip systems, and 3D cell cultures. These innovations are reshaping the preclinical research landscape and creating new opportunities for CROs to differentiate their offerings. As these technologies gain wider acceptance and regulatory support, they are expected to drive further growth in the preclinical CRO market, particularly among companies developing cutting-edge therapies that require sophisticated preclinical validation.

Scope of the Study

The report analyzes the Preclinical Contract Research Organizations market, presented in terms of market value (US$ Million). The analysis covers the key segments and geographic regions outlined below.

Segments

Service (Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology, Other Services); End-Use (Biopharma Companies, Government & Academic Institutes, Medical Device Companies)

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Toxicology Testing Service segment, which is expected to reach US$3.2 Billion by 2030 with a CAGR of a 7.4%. The Bioanalysis & DMPK Studies segment is also set to grow at 7.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.9 Billion in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $1.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Preclinical Contract Research Organizations Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preclinical Contract Research Organizations Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Preclinical Contract Research Organizations Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Global Preclinical Contract Research Organizations Market such as Envigo Corporation, Eurofins Scientific, ICON Plc, Laboratory Corporation of America, Inc., Medpace, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 33 companies featured in this Global Preclinical Contract Research Organizations Market report include:

  • Envigo Corporation
  • Eurofins Scientific
  • ICON Plc
  • Laboratory Corporation of America, Inc.
  • Medpace, Inc.
  • MPI research
  • PARAXEL International Corporation
  • Pharmaceutical Product Development (PPD), LLC
  • PRA Health Sciences, Inc.
  • Wuxi AppTec

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Preclinical Contract Research Organizations - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Growing Consumer Demand for Enhanced Athletic Performance Drives Adoption of Pre-Workout Supplements
  • Increasing Focus on Clean Label Ingredients Expands Market Opportunities for Natural and Organic Pre-Workout Formulations
  • Rising Popularity of High-Intensity Interval Training (HIIT) Spurs Demand for Effective Pre-Workout Supplements
  • Expansion of the E-Commerce Market Strengthens the Business Case for Online Sales of Pre-Workout Supplements
  • Technological Advancements in Ingredient Sourcing Propel Innovation in Pre-Workout Formulations
  • Growing Awareness of Mental Focus and Cognitive Benefits Drives Demand for Nootropic Ingredients in Pre-Workout Supplements
  • Increasing Interest in Customizable Supplements Expands Addressable Market for Personalized Pre-Workout Formulations
  • Rising Consumer Preferences for Non-Stimulant Pre-Workout Options Propels Growth in Caffeine-Free Products
  • Expansion of Health and Fitness Influencer Marketing Strategies Drives Consumer Adoption of Pre-Workout Supplements
  • Growing Use of Social Media and Online Communities for Fitness Advice Expands Market for Pre-Workout Recommendations
  • Rising Demand for Convenient and Ready-to-Drink Pre-Workout Formulations Drives Innovation in Packaging Solutions
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Preclinical Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Preclinical Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Bioanalysis & DMPK Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Bioanalysis & DMPK Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Bioanalysis & DMPK Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Government & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Government & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Government & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 22: World Preclinical Contract Research Organizations Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 23: World Recent Past, Current & Future Analysis for Compound Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Compound Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Compound Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Chemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Chemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Chemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Safety Pharmacology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Safety Pharmacology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for Safety Pharmacology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: USA Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: USA 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
JAPAN
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
CHINA
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
EUROPE
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Preclinical Contract Research Organizations by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Preclinical Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
FRANCE
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: France Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: France 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
GERMANY
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Germany 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Italy 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: UK Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: UK 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Preclinical Contract Research Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies, Compound Management, Chemistry, Safety Pharmacology and Other Services for the Years 2014, 2024 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2014, 2024 & 2030
REST OF WORLDIV. COMPETITION

Companies Mentioned

  • Envigo Corporation
  • Eurofins Scientific
  • ICON Plc
  • Laboratory Corporation of America, Inc.
  • Medpace, Inc.
  • MPI research
  • PARAXEL International Corporation
  • Pharmaceutical Product Development (PPD), LLC
  • PRA Health Sciences, Inc.
  • Wuxi AppTec

Table Information